cas 1184589-25-0|| where to buy (4-(1-methyl-1H-pyrazol-4-yl)phenyl)methanamine

Название продукции:(4-(1-methyl-1H-pyrazol-4-yl)phenyl)methanamine

IUPAC Name:1-[4-(1-methyl-1H-pyrazol-4-yl)phenyl]methanamine

Упаковочная единица	Доступно для заказа	Цена ($)	Количество
CM362822-1g	in stock	ưȁƦ

Только для использования в НИОКР..

Форма запроса

Химическое название

Номер CAS

Количество*

Необходимые спецификации*
(% пробы, категория материала и т.д.)

Контактное лицо*

Электронная почта*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 1184589-25-0 regularly via the above email.

Дополнительные примечания

Verification code*

refresh

: Номер CAS:1184589-25-0; Молекулярная формула:C11H13N3; Точка плавления:-; Smiles-код:CN1C=C(C=N1)C1=CC=C(CN)C=C1; Плотность:

: Номер в каталоге:CM362822; Молекулярная масса:187.25; Точка кипения:; Номер Mdl:; Хранение:

: Pyrazoles; Pyrazoles are organic compounds of the general formula C3H3N2H. It is a five-membered heterocycle consisting of three carbon atoms and two adjacent nitrogen atoms. As an H-bond-donating heterocycle, pyrazole has been used as a more lipophilic and metabolically more stable bioisomer of phenol. Pyrazoles have attracted more and more attention due to their broad spectrum of action and strong efficacy.; Pyrazone; Custom pyrazone for customers from all over the world are our main business.

: IDRX-42; IDRx announces $120 million series B financing to advance potential best-in-class new treatment for gastrointestinal stromal tumor (GIST). IDRX-42 is a potent, oral, highly selective KIT inhibitor targeting all major categories of activating and resistance mutations in patients with KIT-mutant GIST (including variants in exons 9, 11, 13 and 17). IDRX-42 was granted Orphan Drug designation by the FDA for the treatment of GIST. IDRX-42 is currently being evaluated in StrateGIST 1, a first-in-human Phase 1/1b study.
In preclinical studies, IDRX-42 demonstrated superior antitumor activity compared to imatinib, the current first-line of therapy, in GIST human xenograft models expressing mutations in KIT exons 9 and 11. In xenograft models expressing secondary resistance mutations in KIT exon 13 or 17, IDRX-42 treatment resulted in potent and dose-dependent antitumor activity superior to the second-line standard of care agent, sunitinib.